Alx oncology to host investor call and webcast on october 3, 2023 to share interim phase 2 aspen-06 clinical trial results of evorpacept for the treatment of advanced her2-positive gastric cancer

South san francisco, calif., oct. 02, 2023 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or the “company”) (nasdaq: alxo), an immuno-oncology company developing therapies that block the cd47 immune checkpoint pathway, today announced the hosting of an investor call and webcast on tuesday, october 3rd at 8:00 am edt to share interim phase 2 aspen-06 clinical trial results of evorpacept for the treatment of advanced her2-positive gastric cancer.
ALXO Ratings Summary
ALXO Quant Ranking